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Abstract
Background: Solitary plasmacytoma (SP) of the bone is a rare plasma-cell neoplasm. There are
no conclusive data in the literature on the optimal radiation therapy (RT) dose in SP. Therefore, in
this large retrospective study, we wanted to assess the outcome, prognostic factors, and the
optimal RT dose in patients with SP.
Methods: Data from 206 patients with bone SP without evidence of multiple myeloma (MM) were
collected. Histopathological diagnosis was obtained for all patients. The majority (n = 169) of the
patients received RT alone; 32 chemotherapy and RT, and 5 surgery. Median follow-up was 54
months (7–245).
Results: Five-year overall survival, disease-free survival (DFS), and local control was 70%, 46%, and
88%; respectively. Median time to MM development was 21 months (2–135) with a 5-year
probability of 51%. In multivariate analyses, favorable factors were younger age and tumor size < 5
cm for survival; younger age for DFS; anatomic localization (vertebra vs. other) for local control.
Older age was the only predictor for MM. There was no dose-response relationship for doses 30
Gy or higher, even for larger tumors.
Conclusion: Younger patients, especially those with vertebral localization have the best outcome
when treated with moderate-dose RT. Progression to MM remains the main problem. Further
investigation should focus on adjuvant chemotherapy and/or novel therapeutic agents.
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Solitary plasmacytoma (SP) is a rare plasma-cell neo-
plasm [1]. There are two separate entities, dependent on
the location of the lesion originating in either bone or
extramedullary soft tissue [2]. It is defined as a prolifera-
tion of monoclonal plasma cells without evidence of sig-
nificant bone-marrow plasma-cell infiltration [1]. Bone
SP is characterized by a unique lesion involving any part
of the squeleton, most commonly in the spine.
Recommendations for the choice of treatment modalities
in this radiosensitive disease [3] are based mainly on data
from retrospective studies often considering relatively
small numbers of patients, with a limited ability to make
any robust conclusions [4,5], and only one prospective
study including 53 patients [6].
Definitive radiation therapy (RT) is the treatment of
choice for solitary plasmacytoma giving adequate local
control. However, with respect to long-term outcome, it is
known that bone plasmacytoma progresses more fre-
quently to multiple myeloma (MM) than soft-tissue plas-
macytoma [7-9].
There are no conclusive data in the literature on the opti-
mal RT dose in SP. Many authors reported a wide range of
doses varying from 30–66 Gy [10-12]. Most centers use 50
Gy or more to treat SP, without any strong evidence
whether doses higher than 30 Gy are needed.
We report herein the results of a retrospective multicenter
study of a large cohort of patients with bone SP from
European and North American centers, assessing treat-
ment approaches, radiation dose-response effects and dif-
ferent prognostic factors for survival, myeloma
progression, and patterns of local failure.
Methods
Between 1977 and 2001, 206 adult patients consecutively
treated for a bone SP without evidence of MM were col-
lected in a retrospective multicenter study of the Rare Can-
cer Network (RCN). The review board of the RCN granted
ethical approval for this study, and individual centers
obtained individual ethical approval according to their
local regulations for retrospective studies. The study
included all patients with a new diagnosis of bone SP and
considered candidates for curative RT. According to the
new International Myeloma Working Group (IMWG) cri-
teria [13], a patient can be considered to have a bone SP if
there is no M-protein in serum and/or urine (a small M-
component may sometimes be present); only a single area
of bone destruction related to clonal plasma cells; no
bone marrow infiltration; normal skeletal survey includ-
ing spine and pelvic MRI; and no end-organ damage other
Table 1: Characteristics of 206 patients with bone plasmacytoma
Number of patients Percentage
Staging Work-up
Bone-marrow assessment 206 100
Standard X-rays 167 82
Computer tomography 135 67
Serum immunoglobulins 120 58
Immunosubtraction 131 64
MRI 76 37
Bone scintigraphy 60 29
Site of lesion
Vertebrae 102 50
Pelvis 26 12
Ribs 18 9
Upper extremities 16 8
Maxillary bone 13 6
Skull 11 5
Lower extremities 10 5
Sternum 10 5
Surgical intervention
Biopsy 137 67
Partial resection 66 32
Complete resection 3 1
Treatment
RT alone 169 82
CT+RT 32 16
Surgery alone (+CT in one) 5 2
MRI: magnetic resonance imaging, RT: radiation therapy, CT: chemotherapy.Page 2 of 9
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and conducted before the publication of the IMWG guide-
lines, only the following criteria were used: a patient was
considered to have a bone SP if there is a biopsy-proven
solitary bone lesion; <10% plasma cells in the bone-mar-
row biopsy; no additional pathological lesions in the skel-
etal diagnostic work-up; no anemia; and normal blood
chemistry. The median age was 60 years (range: 18–87),
and the male-to-female ratio was 1.82. Pathological diag-
nosis was obtained in all patients, by biopsy in 137, par-
tial resection in 66, and complete resection in 9 patients.
Spinal column was the most frequent tumor site (n =
102). Initial diagnostic work-up was done according to
standard recommendations current at the time of diagno-
sis. Magnetic-resonance imaging (MRI) was used only in
76 patients (37%). The largest diameter of the lesion was
recorded in 104 patients (50%), and its median value was
5 cm (range: 1–18 cm). It was 5 cm or more in 59 patients
(29%), and less than 5 cm in 45 (22%). Serum immu-
noglobulin levels, a factor which indicates the possibility
of occult disseminated disease, were reported in 120
patients (median 6.5 g/l; range: 0–82); however, mye-
loma (M) protein levels were not assessed following RT
[11]. In this series, serum immunoglobulin level more
than 20 g/l was recorded only in 18 patients. Serum elec-
trophoresis and immunofixation were performed in 131
patients. Beta-2 microglobulin data were recorded only
for 60 patients. Human immunodeficiency-virus testing
was done in only 5 patients, and all were negative. Table
1 summarizes the characteristics of all patients. Median
follow-up was 54 months (range: 7–245).
Treatment
All but 5 patients received RT. Surgical treatment was
implemented in 69 (33%) patients (partial resection in
66, and complete excision in 3). Chemotherapy was given
in 32 (16%) patients. The planning RT volume included
the radiologically visible gross tumor volume with a suffi-
cient margin. For vertebral SP, the planning RT volume
included one vertebra above and below the involved ver-
tebra. No attempt was made to cover regional lymph
nodes. Median dose was 40 Gy (range: 20–64); median
number of fractions was 20 (range: 4–33) using a median
dose of 2 Gy per fraction (range: 1.25–5). To facilitate the
comparison of the different fractionation schedules used
by different centers, we computed the 2-Gy per fraction
biologically effective dose (BED) according to the linear-
quadratic model: BED = nd(1+ [d÷α/β]); where α/β = 10
for plasmacytoma; n = number of fractions; and d = dose
per fraction [14]. Median BED was 40.00 Gy (range:
18.75–66.00).
Six cycles (range: 1–12) of chemotherapy consisting of
melphalan and prednisone (n = 23; 72%), vincristine,
doxorubicin and dexamethasone (VAD) (n = 7; 22%),
and other combinations (n = 2; 6%) were administered in
32 (16%) patients.
Statistical methods
Overall survival (OS), disease-free survival (DFS), local
control, and time to MM progression were estimated
using the product-limit method [15]. Time to any event
was measured from the date of histological diagnosis. The
events were death (all causes) for OS, and death (all
causes) or relapse and/or progression to MM for DFS. For
the local control rate, the event consisted of local failure,
censoring patients without local relapse. For progression
to MM, all patients without MM progression were cen-
sored. Confidence intervals (CI) were calculated from
standard errors. Differences between groups were assessed
using the log rank test [16]. Multivariate analyses were
done using the Cox stepwise-regression analysis to deter-
mine the independent contribution of each prognostic
factor [17].
Results
Local control
Median time to local relapse was 20 months (range: 2–
148), and was observed in 13% of the patients (n = 27).
No regional lymph node relapse was observed. The 5- and
Table 2: Distribution of local relapses according to biologically effective radiation dose*
All patients (n = 206) Tumors ≥ 5 cm (n = 59)
Radiation dose (Gy) Number of patients Local relapse (%) Number of patients Local relapse (%)
No RT** 5 4 (80%) 1 1 (100%)
<30 25 2 (8%) 2 0
≥ 30 – <40 55 5 (9%) 17 3 (18%)
≥ 40 – <50 65 8 (12%) 15 3 (20%)
≥ 50 56 8 (13%) 24 4 (17%)
RT: radiation therapy
*biologically effective dose (BED) according to the linear-quadratic model.13
BED = nd(1+ [d÷α/β]) where n = number of fractions, d = dose per fraction, and α/β = 10 for plasmacytoma.
**All patients treated with surgery alone (with chemotherapy in one).Page 3 of 9
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Table 3: Univariate analyses (logrank test)
n 10-yr. 
OS (%)
%95 CI 
(%)
p-value 10-yr. 
DFS (%)
%95 CI 
(%)
p-value 10-yr. 
LC (%)
%95 CI 
(%)
p-value 10-yr. 
MM (%)
%95 CI 
(%)
p-value
All 
patients
206 52 43–61 25 15–35 79 69–89 72 62–82
Age (year)
≤ 60 103 63 50–76 <0.0001 29 16–42 0.02 79 64–94 0.46 67 53–81 0.007
>60 03 34 19–49 22 9–35 79 67–91 76 62–90
Gender
Fem
ale
73 52 36–68 0.98 38 23–53 0.79 88 79–97 0.60 58 43–73 0.77
Male 133 49 37–61 23 13–33 75 62–88 74 63–85
Site of plasmacytoma
Vert
ebra
102 52 38–66 0.99 19 4–34 0.89 89 79–98 0.07 79 64–94 0.39
Othe
r
104 48 35–61 28 16–40 78 68–88 66 53–79
Largest tumor dimension (cm)
<5 45 67 36–98 0.001 24 7–41 0.73 87 75–99 0.47 79 58–100 0.31
≥ 5 59 57 42–72 34 19–49 78 65–91 58 42–74
NA 102 33 19–47 16 0–33 73 50–96 80 64–96
IgM subtype
Kapp
a
59 49 19–47 0.57 0 - 0.57 60 24–94 0.49 91 75–100 0.36
Lam
bda 
100
31 61 40–81 35 16–54 87 69–100 65 46–84
NA 116 49 37–61 22 20–44 84 75–93 64 52–76
Type of treatment
RT 
alon
e
169 51 40–62 0.49 27 16–38 0.92 78 66–90 0.27 71 60–82 0.93
CT 
+ RT 
100
32 43 20–66 15 0–39 93 84- 77 54–100
2 Gy/fr equivalent RT dose (Gy)a
≥ 50 56 47 28–66 0.50 26 10–42 0.06 82 68–96 <0.0001
b
71 55–87 0.25
≥ 40 
and 
<50
65 55 34–76 25 6–44 67 40–94 78 59–97
≥ 30 
and 
<40
55 46 28–64 32 16–48 90 81–99 63 47–79
<30 25 37 13–61 17 0–43 96 88–100 81 53–100
No 
RTc
5 0 - 0 - 0 - 33 0–86
OS: overall survival; CI: confidence interval; DFS: disease-free survival; LC: local control; MM: progression to multiple myeloma; NA: not available; 
CT: chemotherapy; RT: radiation therapy abiologically effective dose (BED) according to the linear-quadratic model.13 BED = nd(1+ [d÷α/β]) where 
n = number of fractions, d = dose per fraction, and α/β = 10 for plasmacytoma. bnot significant when excluding patients not receiving radiation 
therapy. cAll patients treated with surgery alone (with chemotherapy in one).
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83–93) and 79% (95% CI: 69–89), respectively. Ten-year
local control according to the RT dose and to other candi-
date factors is shown in Tables 2 and 3. When considering
patients with tumor diameters of 5 cm or larger (n = 59),
likewise there was no clear benefit from higher doses.
However, patients with vertebral lesions seemed to have a
better outcome in terms of local control (Tables 3 and 4).
There were 4 (80%) local relapses out of 5 patients who
were treated with surgery with or without chemotherapy
compared to 21 (14%) out of 148 who received RT alone,
and 2 (7%) out of 30 who received RT and chemotherapy.
Surgery (RT vs. partial or complete resection and RT) did
not influence the 10-year probability of local control
(80% [95% CI: 71–89] vs. 74% [95% CI: 47–100], p =
0.35). After adjusting RT dose to 2 Gy per fraction biolog-
ically equivalent dose, no dose-response relationship was
observed for doses higher than 30 Gy (15 x 2 Gy; Fig. 1,
Table 2). Among 201 irradiated patients, there were 2
(7%) local failures out of 29 patients treated with = 30 Gy
vs. 20 (12%) out of 168 treated with > 30 Gy.
Progression to multiple myeloma
Median time to development of MM was 21 months
(range: 2–135). One hundred and forth (104) patients
developed MM with a 5- and 10-year projected probabil-
ity of 51% (95% CI: 43–59) and 72% (95% CI: 62–82),
respectively (Fig. 2). Among the 120 patients where base-
line immunoglobulin levels were recorded (median: 6.5
g/l; range: 0–82), 10 of 18 patients whose levels were
above 20 g/l developed MM progression compared to 53
of 102 whose immunoglobulin levels were 20 g/l or less
(chi-square: 0.079; p = 0.78). Moreover, in a logistic
regression analysis assessing the influence of baseline
serum immunoglobulin level on the development of MM,
no significant correlation was found (R-square: 0.002; p =
0.60). Ten-year probability of progression to MM accord-
ing to the type of SP and to other factors is shown in Table
3. The only unfavorable factor for myeloma development
was older age (> 60 years) in univariate analyses. The 10-
year probability of progression to MM was not influenced
by anatomical location (79% for vertebra vs. 67% other; p
= 0.73). MRI examination during staging work-up was not
significantly associated with the 10-year probability of
progression to MM (71% in both groups, p = 0.22).
Survival
At the time of analysis, 135 patients were alive (50 with
disease), and 71 had died (54 died of disease including 2
with unknown causes, 16 related to intercurrent disease,
and 1 from cardiopulmonary disease probably related to
mediastinal RT).
In all patients, the 5- and 10-year probability of OS were
70% (95% CI: 63–77) and 50% (95% CI: 40–60), respec-
tively; and for 5- and 10-year DFS, 46% (95% CI: 38–54)
and 25% (95% CI: 16–34), respectively.
In univariate analyses, statistically significant best factors
influencing the OS were younger age (60 years or
younger), and tumor size (< 5 cm). Ten-year probabilities
of OS and DFS according to different prognostic factors
are shown in Table 3.
Multivariate analyses
Multivariate analyses revealed that the best independent
factors predicting the outcome were: younger age (RR =
0.59; p < 0.00001) and tumors less than 5 cm (RR = 0.56;
p = 0.0007) for OS; younger age (RR = 0.79; p = 0.02) for
DFS; and vertebra localization (RR = 0.63; p = 0.04) for
local control. Older age (RR = 0.78; p = 0.01) was the only
independent predictor for MM development.
Toxicity
Early side effects according to CTC v2.0 depended on the
irradiated anatomical regions [18]. Grade 1 toxicity was
observed in 46 patients (22%), grade 2 in 14 (7%), and
grade 3 in 4 (2%).
According to the RTOG/EORTC late effect scoring system
[19], grade 1 toxicity was observed in one patient (asymp-
tomatic bone necrosis), no grade 2 toxicity, and grade 3
toxicity in 2 (femoral head necrosis in one, and xerosto-
Actuarial local control rate according to biologically equiva-len  dose at 2 Gy per f ction (no radiation ther p : solid/double-dot line; <30 Gy: solid li e; 30–39 Gy: dashed line; 40–49 Gy: solid/single-do  line; = 50 Gy: dotte  lin ) in 206 patient  wi h solitary bone plasmacytoma (p < 0.0001 but not significant when exc udi g non r adiated pa i nt )Fig r  1
Actuarial local control rate according to biologically equiva-
lent dose at 2 Gy per fraction (no radiation therapy: solid/
double-dot line; <30 Gy: solid line; 30–39 Gy: dashed line; 
40–49 Gy: solid/single-dot line; = 50 Gy: dotted line) in 206 
patients with solitary bone plasmacytoma (p < 0.0001 but not 
significant when excluding non irradiated patients).Page 5 of 9
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observed in one patient who died from cardiopulmonary
disease probably related to mediastinal RT toxicity.
Discussion
We recently reported our experience on a series of 258
patients including bone and extramedullary SP [20]. In
the present study, we wanted to specifically assess differ-
ent treatment approaches, radiation dose-response effects;
and different prognostic factors in patients with bone
plasmacytoma. Several factors are reported to influence
the outcome of SP in the literature [2,8,10,12,20-24].
Despite good local control with RT, patients with bone SP
progresses to MM more frequently than those with
extramedullary SP [7,10]. Many questions remain unan-
swered about prognostic factors influencing the outcome
and radiation dose-response, probably due to the limited
number of patients included in reported series [9,12,24].
This may be related to the lack of routine use of MRI to
exclude occult lesions at initial diagnosis [25,26]. MRI
was done in only 33% of our patients (Table 1). Staging
using MRI to exclude multiple lesions has contributed in
recent years to more accurate diagnosis of SP, since only
the patients with truly solitary involvement are eligible for
curative RT [25,26]. This may also help radiation oncolo-
gists to define target radiation volumes with higher preci-
sion [27]. Unfortunately, in this study, whether MRI
examination was done or not did not result in an
improved ability to predict progression to MM. However,
it was not clear how often MRI was done to define the
local extent of disease, rather than for the detection of
occult disease in other bony sites such as the spine and
pelvis. Nevertheless, in our patients who had an MRI
examination, no occult asymptomatic MM lesions were
detected.
There is limited information in the literature regarding the
outcome of elderly patients with myeloma. Some series
indicate that advanced age is clearly associated with poor
survival whereas others do not [28]. In our series older age
(>60 years) was found to be a bad prognostic factor, either
in univariate or multivariate analyses, in terms of OS,
DFS, or progression to MM. This difference may be related
to several reasons. In terms of survival, older patients who
develop MM are possibly treated with "less aggressive"
treatments, or not included in prospective trials compared
to younger patients [29]. However, it is difficult to find an
explanation why our patients older than 60 years develop
MM more frequently than the younger ones.
Patients in this study seemed to develop MM in two peaks.
A first peak during the first three years post treatment is
probably due to undetected asymptomatic gross disease
becoming more obvious; a second peak corresponding to
a progression of previously occult disease is observed after
6–9 years (Fig. 2). A number of patients showed very late
myeloma progression, even after 10 years. Of note, while
vertebral disease has been reported to be a poor prognos-
tic factor compared to other bony localizations [7], in our
series 50% of bone SP were located in the axial skeleton
but no difference in terms of progression to MM was
observed. However, in multivariate analysis, patients in
our series with vertebral lesions had a better local control
compared to other anatomical locations (Table 4).
Progression to MM has been reported to be less frequent
in younger patients, whose survival is also better
[10,24,30,31]. Our study confirmed these reports, with
progression to MM seen more frequently in older patients,
and improved survival in younger patients (Fig. 3, Table
3). However, local failure did not depend on age.
Baseline immunoglobulin (M protein) levels are reported
to be a predictive factor of occult disseminated disease,
and almost all experts agree that an M protein level of 20
g/l is crucial for the definition of SP [11,13]. In our series,
only 18 patients had an M protein level above 20 g/l, and
no difference in terms of MM development was observed
between patients with M protein levels above and below
20 g/l. Furthermore, patients showing persistent M pro-
tein levels for more than one year after RT are prone to
progress to MM [30,32]. This factor could not be assessed
in our series because we did not have adequate data on M
protein level responses to treatment, and the correlation
of progression to MM with M protein persistence.
Tumor size is reported to be an important prognostic fac-
tor in terms of local control. Tsang et al [10] reported a
Actuarial probability of progression to multiple myeloma in 206 patientsFig re 2
Actuarial probability of progression to multiple myeloma in 
206 patients.Page 6 of 9
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studies did not find tumor size to be a factor [32]. In our
series, local control was higher for plasmacytomas meas-
uring less than 5 cm (91%) than for those 5 cm or higher
(73%). It is important to note that size was not reported
for 112 (43%) of the patients in our study (Table 3).
In a large review of over 400 publications from 1905 to
1997, Alexiou et al [33] reported evidence that surgery
alone gave the best results for extramedullary bone plas-
macytoma when clear surgical margins were obtained. In
the present series, 94 patients were treated by surgery with
(n = 86) or without RT (n = 8). Nine (3%) had a complete
resection with negative margins; of these, only one
received adjuvant RT, and seven relapsed. This finding
argues against proposing surgery alone, even in cases
where complete resection is achieved.
While radiation therapy is the treatment of choice for sol-
itary plasmacytoma, the evidence of its efficacy is solely
based on small retrospective studies [34]. There is no clear
RT dose-response relationship in the literature. The analy-
sis performed by Mendenhall et al [22] suggested a mini-
mum dose of 40 Gy for optimal local control. Despite
little evidence for a dose-response relationship above 30–
40 Gy [8,21,24], some authors propose doses between 40
and 50 Gy for small lesions, and higher doses for larger
tumors [23,26,34]. While Tsang et al [10] reported that
there was no convincing dose-response relationship
above 35 Gy for small lesions, they concluded that local
control was related to the size of the lesion and suggested
giving higher doses or combined modality treatment for
bulky tumors. This has also been proposed by other
groups [8].
Our data showed no correlation between local failure and
radiation dose, even for large tumors (Fig. 1, Table 2). Due
to its retrospective nature, these results should be inter-
preted with caution. However, it included a large number
of patients treated with a wide spectrum of RT doses, with
the finding that 30 Gy in 2-Gy fractions, or a biologically
equivalent regimen was sufficient. It appears from this
study that administering a higher radiation dose may be
unable to overcome the negative prognostic impact of a
bulky tumor on local control, in comparison with smaller
tumors (Table 2). In addition to size, it is possible that
other poorly documented factors (e.g. local invasiveness,
proliferation rate, or morphologic grade) also impact on
the risk of local relapse, and are confounding factors in a
dose-response analysis.
Chemotherapy, which is not considered as a standard of
care in patients with SP, has been proposed by some
investigators in the initial management of bone plasmacy-
toma. Only one prospective study reported a benefit with
combined chemotherapy and RT compared to RT alone
[6]. The chemotherapy used consisted of melphalan-pred-
nisone given every six weeks for three years. Although a
limited number of patients was included (n = 53), this
study concluded that combined radiochemotherapy
seems to increase remission and survival duration.
Targeting the mechanisms that control angiogenesis,
which has an integral role in the pathophysiology of
hematologic malignancies, could be an innovative thera-
peutic approach in the treatment of SP. Kumar et al [35]
reported high-grade angiogenesis in 64% of tumors in
their series of 25 bone SP patients, and found that angio-
genesis is highly correlated with progression to MM.
Therefore, antiangiogenic compounds such as thalido-
mide, vascular-endothelial growth-factor, or proteasome
inhibitors may be promising in this disease.
Conclusion
Overall, the results obtained in this study, to our knowl-
edge the largest series in the literature, are in accordance
with other published series [4,5,8,9,12,21,23,24].
Although high rates of local control were obtained, sur-
Table 4: Multivariate analysis* (Cox model) in 201 irradiated patients
Covariable OS DFS LC MM
RR p-value RR p-value RR p-value RR p-value comment
Age (years) 0.59 <0.00001 0.79 0.02 - - 0.78 0.01 ≤ 60 years 
better
Localization 
(vertebra 
vs.other)
- - - - 0.63 0.04 - - vertebra 
better
Tumor size 
(cm) (<5 vs. 
≥5)
0.56 0.0007 - - - - - - <5 cm 
better
*including age, gender, localization, tumor size, IgM subtype, type of treatment, and biologically equivalent radiation dose.
OS: overall survival; DFS: disease-free survival; LC: local control; MM: progression to multiple myelomaPage 7 of 9
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Only a large prospective study conducted by collaborative
groups could answer the unresolved questions in this rel-
atively rare disease. Following a complete staging work-
up, which may include very sensitive imaging tools such
as positron-emission tomography [36,37], current evi-
dence supports the use of involved-field moderate-dose
radiation therapy. Future investigation in phase II or III
prospective trials should focus on the use of adjuvant
chemotherapy and/or novel therapeutic agents.
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